
Medical cannabis in the UK: what Boots’ entry into the market means for patients
Granskad av Dr Colin Tidy, MRCGPFörfattad av Thomas Andrew Porteus, MBCSUrsprungligen publicerad 18 Nov 2026
Uppfyller patientens redaktionella riktlinjer
- Ladda nerLadda ner
- Dela
- Language
- Diskussion
- Ask Patient
- Ljudversion
- Lägg till i föredragna källor på Google
Medical cannabis has been available on prescription in the UK since 2018. As Boots enters the market, we look at how treatment works, who might be eligible, and what patients should know before considering it.
Videoval för HälsonyheterVideobibliotek
Boots has become the first major UK high street pharmacy retailer to launch a medical cannabis service, marking a significant development in the growing private healthcare market.
Its new service, SureLeaf, is available through Boots Online Doctor and offers specialist assessment and treatment for eligible adults aged 25 and over living with certain long-term conditions, including chronic pain, generaliserat ångestsyndrom, och sömnlöshet.
Patients must have tried conventional treatments without achieving adequate symptom relief. Those who meet the initial criteria will undergo a clinical assessment and video consultation with a consultant on the General Medical Council's (GMC) Specialist Register. Any proposed prescription will also be reviewed by a multidisciplinary clinical team, including a second independent consultant.
Patients receiving treatment will have an initial review after 28 days, followed by reviews at least every three months.
Boots is also exploring a research collaboration with the University of Nottingham to investigate patient outcomes, prescribing practices, and the use of medical cannabis for chronic pain.
The announcement could help bring medical cannabis into more mainstream conversations. But what does it actually mean for patients, and what should you know before considering treatment?
Medical cannabis has been legal in the UK since 2018
Cannabis-based products for medicinal use have been legally available on prescription in the UK since November 2018.
The change followed growing pressure to improve access for patients, particularly children with severe epilepsy, who had experienced difficulties obtaining cannabis-based medicines.
Despite the change in legislation, access through the NHS remains very limited. NHS prescriptions are generally restricted to a small number of circumstances, including certain severe forms of epilepsy, chemotherapy-related nausea and vomiting, and multiple sclerosis-related spasticity where other treatments have not worked.
Private specialist clinics have therefore become the main route for many patients seeking medical cannabis treatment.
Importantly, medical cannabis is not the same as buying cannabis or CBD (cannabidiol) products online or from a health shop. Prescribed cannabis-based medicines are subject to specific regulatory requirements, and many are unlicensed medicines that require specialist oversight.
Who can be prescribed medical cannabis?
There is no single list of conditions for which medical cannabis can legally be prescribed. However, this does not mean it is an appropriate treatment for every condition.
For unlicensed cannabis-based medicines, prescribing must be initiated by, or take place under the direction of, a doctor on the GMC Specialist Register. The doctor must have the relevant knowledge and expertise to assess the patient's needs.
Treatment is generally considered when conventional treatments have not worked, have caused unacceptable side effects, or are unsuitable.
Depending on the individual circumstances, specialists may consider medical cannabis for conditions involving:
Chronic pain - including neuropathic pain.
Multiple sclerosis-related muscle spasticity.
Certain forms of treatment-resistant epilepsy.
Nausea and vomiting associated with chemotherapy.
Other conditions where a specialist believes there may be a clinical benefit.
Boots' new service focuses on eligible adults with chronic pain conditions, generalised anxiety disorder, and insomnia.
Eligibility will depend on an individual's medical history, previous treatments, and clinical assessment. Having a particular diagnosis does not automatically mean someone will be offered a prescription.
What does the evidence say?
Medical cannabis is an area of growing research, but the evidence is not equally strong across all conditions.
Some cannabis-based medicines have established uses. For example, certain licensed products are available for specific forms of epilepsy and multiple sclerosis-related spasticity.
For other conditions, the evidence is more limited. The National Institute for Health and Care Excellence (NICE) guidance highlights the need for further research into the benefits and risks of cannabis-based medicines, particularly where they are being considered for chronic pain.
This is one reason why medical cannabis is not generally considered a first-line treatment.
It is also important to understand that cannabis-based medicines can cause side effects. These may include dizziness, drowsiness, changes in mood, impaired concentration, and problems with memory or coordination. Products containing THC (tetrahydrocannabinol) can also carry a risk of dependence and may affect mental health in some people.
Cannabis-based medicines can interact with other medications, so a specialist needs to consider a patient's wider health and medication history before prescribing.
A prescription should involve an ongoing discussion about potential benefits, risks, and whether treatment is making a meaningful difference.
Why specialist care matters
As more patients become aware of medical cannabis as a potential treatment option, the quality of clinical assessment and ongoing care will be particularly important.
Drugs containing cannabis are not a straightforward solution, and finding an appropriate treatment plan requires more than simply issuing a prescription. Patients need an individual assessment, an understanding of their medical history and regular reviews to monitor their response.
Releaf, a UK-based medical cannabis clinic, believes the growth of the market makes specialist experience and continuity of care increasingly important.
A spokesperson for Releaf said:
"Boots entering medical cannabis is a positive moment for patients. Medical cannabis has been available on prescription in the UK since 2018, yet stigma has stopped many people from asking about it, or knowing a regulated route exists. As more people explore their options, specialist experience matters, because finding the right treatment plan takes careful assessment and regular review, not a one-off prescription."
Releaf says its own approach includes assessment by GMC-registered specialists, multidisciplinary clinical reviews and regular follow-ups. The clinic is regulated by the Care Quality Commission (CQC) and says its integrated pharmacy allows consultation, dispensing, and delivery to operate within one service.
The clinic also uses patient-reported outcome measures (PROMs) to help clinicians monitor progress and review treatment plans.
What should patients consider before seeking treatment?
If you are considering medical cannabis, there are several important things to understand.
It is not available on the NHS for most conditions - although private clinics and services such as Boots offer another route, patients should be aware that consultation, treatment, and medication costs may need to be paid privately.
You will need a specialist assessment - a diagnosis alone is not enough to qualify. A specialist will consider your medical history, previous treatments, other medicines and whether the potential benefits outweigh the risks.
You should expect ongoing monitoring - treatment should be reviewed regularly, with adjustments made where necessary. If it is not helping, your clinician should discuss whether it remains appropriate.
A prescription does not make recreational cannabis legal -medical cannabis must be prescribed to you and obtained through a legitimate regulated route. You should keep your medication in its original packaging and carry evidence of your prescription when appropriate.
Driving requires particular care - cannabis-based medicines can affect your ability to drive. Patients should discuss this with their prescriber and follow the relevant drug-driving rules. Having a prescription does not automatically mean it is safe or lawful to drive if your driving is impaired.
A changing landscape for patients
Boots' arrival is an important development for medical cannabis in the UK. A familiar healthcare brand entering the market could help people feel more comfortable asking questions and understanding the difference between prescribed medicines and unregulated cannabis products.
However, greater visibility should go hand in hand with clear information, responsible prescribing, and realistic expectations.
For patients who have struggled to find effective treatment for long-term conditions, medical cannabis may be an option worth discussing with an appropriately qualified specialist. But it is not suitable for everyone, and more research is needed to understand its benefits and risks across different conditions.
The priority should remain the same regardless of where a patient seeks treatment - safe, evidence-informed care, with proper clinical oversight, and a treatment plan that puts the individual patient first.
Patientval för Hälsonyheter

Tecken och symtom
Living with chronic pain: could treatment at a medical cannabis clinic be an alternative option?
If you live with chronic pain, you’ll likely already know just how debilitating it can be. Whether it’s a form of arthritis, sciatica, or lower back pain, the type of chronic pain you live with can lead to far more than just a painful sensation itself. Chronic pain can also dictate how well you manage to sleep, work and, ultimately, how much you’re able to enjoy your day-to-day life.
by Dr Sue Clenton

Allmän hälsa och livsstil
Varför är medicinsk cannabis så svårt att få tillgång till via NHS?
Medical cannabis has been legal to prescribe in the UK for almost eight years, so why have only a handful of people been able to access it on the NHS?
by The Medical Cannabis Clinicians Society
Om recensentenVisa fullständig biografi

Dr Colin Tidy, MRCGP
Allmänläkare, Medicinsk Författare
MBBS, MRCGP, MRCP (Paediatrics), DCH
Dr Colin Tidy är en NHS-läkare, baserad i Oxfordshire.
Artikelhistorik
Artikeln finns också på Engelska, Tyska, Spanska, Franska, Italienska, Portugisiska, Hindi, Hebreiska, Arabiska, och Svenska.
Next review due: 18 Nov 2029
18 Nov 2026 | Ursprungligen publicerad
Författad av:
Thomas Andrew Porteus, MBCSGranskad av
Dr Colin Tidy, MRCGP
Dela dina tankar eller erfarenheter med andra i vår patientgemenskaper.
Anmäl dig till Patientens nyhetsbrev
Din veckovisa dos av tydliga, pålitliga hälsoråd - skrivna för att hjälpa dig känna dig informerad, självsäker och i kontroll.
Genom att prenumerera accepterar du våra Sekretesspolicy. Du kan avsluta prenumerationen när som helst. Vi säljer aldrig dina uppgifter.
